Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31515495 | 0.74 | PARP1 (0.48) | PARP1CYP1A2CHEK1GSK3B | |
| SCHEMBL7369654 | 0.74 | PARP1 (0.48) | PARP1CYP1A2CHEK1GSK3B | |
| SCHEMBL1556616 | 0.72 | ALDH1A1 (0.60) | PARP1CYP1A2 | |
| SCHEMBL30273087 | 0.70 | PARP1 (0.53) | PARP1CYP1A2 | |
| SCHEMBL6429242 | 0.70 | ALDH1A1 (0.49) | PARP1CYP1A2 | |
| SCHEMBL31330117 | 0.70 | PARP1 (0.44) | PARP1CYP1A2 | |
| SCHEMBL12638629 | 0.70 | PARP1 (0.41) | PARP1CYP1A2LCKPRKACACSNK2A2 | |
| SCHEMBL14647134 | 0.69 | PARP1 (0.50) | PARP1CYP1A2 | |
| SCHEMBL14647112 | 0.69 | PARP1 (0.46) | PARP1CYP1A2LCKPRKACACSNK2A2 | |
| SCHEMBL15721658 | 0.68 | PARP1 (0.46) | PARP1CYP1A2LCKPRKACACSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-20230116370-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-11045562-B2 | Radiolabelled mGluR2/3 PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-29 | — | — | US | disclosed |
| US-20210177995-A1 | RADIOLABELLED mGluR2 PET LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-17 | — | — | US | disclosed |
| US-11033641-B2 | Radiolabelled mGluR2/3 pet ligands | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-15 | — | — | US | disclosed |
| US-10967078-B2 | Radiolabelled mGluR2 PET ligands | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-20200306389-A1 | RADIOLABELLED mGluR2/3 PET LIGANDS | JANSSEN-CILAG, S.A. (ES) | 2020-10-01 | — | — | US | disclosed |
| US-20200261450-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| EP-3004107-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016016395-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016383-A1 | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016381-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016380-A1 | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016382-A1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-04 | — | — | WO | disclosed |
| EP-2861597-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014195311-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-11 | — | — | WO | disclosed |
| CN-103703002-A | Novel compound having parp inhibitory activity | SANTEN PHARMACEUTICAL CO LTD | 2014-04-02 | — | — | CN | disclosed |
| WO-2013174822-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045562-B2 | Radiolabelled mGluR2/3 PET ligands | GRM3, GRM2, GRM1 | PARP1 4785/4885CYP1A2 3179/4885CHEK1 4263/4885 |
| US-10967078-B2 | Radiolabelled mGluR2 PET ligands | GRM2, GRM3, GRM1 | PARP1 4790/4885CYP1A2 3575/4885CHEK1 4541/4885 |
| US-20260060985-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS3, LGALS1, LGALS2 | PARP1 2782/4885CYP1A2 3266/4885CHEK1 1455/4885 |
| US-20230116370-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS1, LGALS2, LGALS3 | PARP1 1233/4885CYP1A2 2667/4885CHEK1 3040/4885 |
| US-20200306389-A1 | RADIOLABELLED mGluR2/3 PET LIGANDS | GRM3, GRM2, GRM5 | PARP1 4741/4885CYP1A2 3005/4885CHEK1 4343/4885 |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | PARP1 1233/4885CYP1A2 2667/4885CHEK1 3040/4885 |
| US-20200261450-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | PARP1 4577/4885CYP1A2 2901/4885CHEK1 4580/4885 |
| US-11033641-B2 | Radiolabelled mGluR2/3 pet ligands | GRM3, GRM2, GRM5 | PARP1 4741/4885CYP1A2 3005/4885CHEK1 4343/4885 |
| US-12377102-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | PARP1 1233/4885CYP1A2 2667/4885CHEK1 3040/4885 |
| US-20210177995-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | PARP1 4790/4885CYP1A2 3575/4885CHEK1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.